The average Class II medical device takes three to five years from concept to market clearance. A Class III device often takes seven years or more. When companies ask how to compress those timelines, the conversation usually turns immediately to FDA review times. That’s the wrong place to focus.
FDA review goals under are 90 FDA days for 510(k)s (with 95% of submissions meeting that target), 150 FDA days for De Novo, and approximately 285 days total for PMAs. Those windows are relatively predictable. What isn’t predictable is the time spent before a submission reaches FDA, and the rework triggered when it comes back with deficiencies.
The companies that consistently get to market faster don’t do so by moving through FDA faster. They do it by making fewer mistakes before they get there.
Key Takeaways
- Most medical device delays occur during pre-submission development, not FDA review.
- Choosing the wrong regulatory pathway is one of the most expensive mistakes a development team can make. It can add years.
- FDA’s Q-Submission program provides direct regulatory feedback before a submission is filed, and a well-prepared Pre-Sub reduces the risk of Additional Information requests, wrong predicate selection, and insufficient testing.
- Design controls, V&V planning, and design for manufacturability work best when they’re built into development from the start, not layered on after engineering is complete.
- Additional engineering capacity at the right phase of development can compress timelines without requiring permanent headcount growth.
Where Time Is Actually Lost
Development timelines in medical devices consistently overrun for a predictable set of reasons. Understanding them is the first step toward avoiding them.
Underestimating development effort. Most timeline failures start at the planning stage. Teams scope the engineering work without fully accounting for design iterations, testing lead times, supplier qualifications, and the time required to build a defensible documentation record. When those gaps surface mid-development, they cascade.
Late design control integration. Design controls under aren’t optional for Class II and III devices, and they aren’t a documentation activity that can be completed after the fact. Teams that defer design control work until submission preparation frequently discover that their records don’t meet the standard, that traceability gaps exist, or that acceptance criteria weren’t defined before testing began. Remediation takes time.
V&V planned too late. Verification and validation protocols that are designed after engineering is finalized often don’t align cleanly with the design inputs they’re supposed to test. Rework follows. Teams that build V&V planning into the development process from the requirements stage avoid this category of delay almost entirely.
Wrong regulatory pathway. Selecting the right FDA submission pathway, whether 510(k), De Novo, or PMA, requires understanding your device’s risk classification, intended use, and the state of the predicate landscape. Selecting the wrong pathway, or discovering mid-development that the assumed pathway isn’t appropriate, can add a year or more to a program.
Incomplete or unclear submissions. Additional Information (AI) requests from FDA occur when submissions are missing required elements, when the predicate selection logic isn’t adequately supported, or when test data doesn’t address the specific risks FDA expects to see covered. Every AI request stops the review clock and adds months.
Get the Regulatory Pathway Right Before Development Begins
Regulatory pathway selection isn’t a submission question. It’s a development planning question, because the pathway determines what evidence you need to generate, how much clinical data is required, and how long the overall program will take.
The three primary pathways for U.S. market entry carry materially different timelines and evidence requirements.
510(k) clearance applies to Class II devices that are substantially equivalent to a legally marketed predicate. FDA review targets 90 FDA days, and most programs should plan for 18 to 36 months total from development start to clearance, accounting for design, testing, and submission preparation. The submission must establish substantial equivalence through comparison of intended use and technological characteristics. Predicate selection is consequential: a weak predicate or a predicate with unresolved performance questions will generate questions.
De Novo classification is the pathway for novel low-to-moderate risk devices without a predicate. FDA review targets 150 FDA days, and total program timelines are typically longer than 510(k) because the submission must establish a new regulatory classification and define special controls. The benefit is that a successful De Novo creates a predicate for future similar devices.
PMA approval is required for Class III devices, those that support or sustain human life, present a potential unreasonable risk of illness or injury, or are novel with insufficient information to provide reasonable assurance of safety and effectiveness through general controls and special controls alone. PMA timelines average 285 days for FDA review, but total program timelines routinely exceed five years because of the clinical evidence requirements.
Getting this decision right early is not a compliance function. It is a core engineering program management decision.
Use FDA’s Q-Submission Program Before You File
FDA’s allows medical device developers to request direct written feedback from FDA on specific regulatory questions before filing a formal submission. This includes feedback on regulatory pathway selection, proposed testing protocols, predicate device selection, clinical study design, and software documentation approach.
A well-prepared Pre-Submission can prevent the most costly category of delays: discovering late in development that your testing approach doesn’t address FDA’s specific concerns, or that your proposed predicate won’t support the substantial equivalence argument you’ve built around it.
FDA’s target for written feedback on Pre-Submissions is 70 to 90 calendar days. That investment of time at the front end of a program regularly pays back multiple times over by preventing AI requests and avoiding late-stage testing gaps. The notes that a well-prepared Pre-Sub can save hundreds of thousands of dollars in avoidable study costs in addition to the timeline benefits.
The Q-Sub is not a guarantee of approval or a substitute for a strong submission, but it reduces uncertainty at exactly the moments when uncertainty is most expensive.
Build Design Controls Concurrently With Development
Design controls are a regulatory requirement. They’re also the documentation infrastructure that makes a device program auditable, transferable, and defensible. The problem is that most teams treat them as a parallel track from engineering, something to be maintained by quality while the engineers do the real work.
The teams that move fastest treat design controls as an engineering activity. Requirements are written and reviewed before design begins. The traceability matrix is built and updated in real time, not reconstructed at submission. Design reviews are real engineering checkpoints with documented outputs, not sign-off rituals at the end of a phase.
The practical reason this matters for timelines is that rework is the most expensive kind of work in device development. A verification test run against an input that was informally modified two months earlier generates a finding that requires analysis, a change record, and potentially a retest. A DHF assembled at the end of a program consistently has gaps that require remediation. Building the record while the work is happening eliminates this category of delay.
For a deeper look at what a defensible Design History File actually requires, see DISHER’s guide: How to Build a Design History File That Survives FDA Scrutiny.
Plan Verification and Validation From the Requirements Stage
Verification and validation planning should begin when design inputs are being written, not after the design is locked. The reason is architectural: V&V protocols need to be built around specific, measurable inputs. When protocols are written after the design is finalized, they frequently expose inputs that aren’t specific enough to test against, or identify testing gaps that require design changes to address.
The other timeline risk in V&V is testing resource lead times. External test labs have backlogs. Biocompatibility studies under ISO 10993 take months. Electrical safety testing and EMC testing require scheduling. Teams that identify their full testing list early, map external dependencies, and schedule resources in advance routinely complete V&V faster than teams that discover test lab availability constraints after protocols are written.
A practical rule: the V&V plan should exist as a living document from the point design inputs are first drafted. Every design input should have a planned method of verification. The plan updates as design evolves, and it drives test lab scheduling as the design stabilizes.
Integrate Design for Manufacturability Early
Design for Manufacturability (DFM) is the practice of designing products with the capabilities and constraints of the manufacturing process in mind from the start. In medical devices, late DFM engagement is a reliable source of schedule impact: a design that performs well in testing but can’t be manufactured consistently, affordably, or to specification requires redesign that pushes back transfer, re-verification, and ultimately launch.
According to , integrating DFM principles early in the development process can reduce total product development cost by 20 to 40 percent. The timeline benefit comes from avoiding the redesign-and-retest cycles that late DFM review generates.
Practically, this means manufacturing engineering should have a seat at the table during design reviews, not just at design transfer. Tolerance stack-up analysis, material selection for processability, assembly complexity, and supplier capability for critical components are all questions that are far cheaper to answer during design than after design is locked.
Design transfer is not the point at which manufacturing becomes involved. It is the point at which manufacturing confirms readiness for production based on engagement that started much earlier.
Bring In Engineering Capacity Strategically
Many medical device development delays are resource problems as much as process problems. A program that has the right engineering skills in house moves faster than one that doesn’t, but building a permanent team for every specialized capability required across a full development cycle isn’t practical for most organizations.
Strategic use of contract engineering resources addresses this directly. The benefit isn’t just bandwidth. An experienced engineering partner brings regulatory familiarity, design process discipline, and a working knowledge of what FDA expects to see in a submission, which translates into first-time quality on documentation and testing that reduces rework and AI requests.
The timing of when external engineering support is engaged matters. Early engagement, during design inputs and design control framework setup, has the highest leverage. Late engagement, brought in to fill gaps before submission, is more expensive and less effective.
The , which reflects how widely medical device companies have adopted this model. The rationale is consistent: access to specialized capabilities at the right phase of development, without permanent headcount growth.
Where 黑料科 Can Help
黑料科 works with medical device manufacturers across device classes and development stages, from early design controls setup and regulatory strategy through V&V execution, design transfer, and submission preparation.
When we join a program, we integrate with your team and bring process discipline alongside engineering capability. That means design controls built right the first time, V&V planned from the requirements stage, and a documentation record built to hold up under FDA review, not assembled against the clock before a submission deadline.
Our Medical Device Product Development Readiness Assessment is a structured way to evaluate where a program stands across product, regulatory, engineering, and manufacturing readiness. It’s a useful starting point for programs that want to understand where timeline risk is concentrated before it materializes.
Written By:
DISHER
Communications Team
DISHER Newsletter
Sign up to receive articles and insights, delivered monthly.
Schedule a no-committment project call
Reach out to discuss your project to find out if DISHER could be a good fit for you.